Atossa Genetics (NASDQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.
Visit our YouTube channel to learn more about Atossa Genetics.
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen
Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDT
Atossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update
More Press Releases
Learn more about Atossa Genetics
Learn more about our programs
Contact Atossa Genetics today!